Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Price, News & Analysis

Angion Biomedica logo

About Angion Biomedica Stock (NASDAQ:ANGN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.00
$10.00
52-Week Range
N/A
Volume
224,800 shs
Average Volume
86,718 shs
Market Capitalization
$30.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

ANGN Stock News Headlines

Angion Biomedica Stock Price History
Akari Therapeutics PLC ADR
I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.
OXBDF Oxford Biomedica plc
8-K: Angion Biomedica Corp.
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CSII, ANGN, OSH, NUVA
See More Headlines

ANGN Stock Analysis - Frequently Asked Questions

Angion Biomedica Corp. (NASDAQ:ANGN) announced its earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.30) by $2.00. The company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $1.08 million.

Angion Biomedica's stock reverse split before market open on Friday, June 2nd 2023.The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Angion Biomedica (ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Angion Biomedica investors own include Evofem Biosciences (EVFM), Plug Power (PLUG), CNS Pharmaceuticals (CNSP), Viking Therapeutics (VKTX), ContextLogic (WISH), Abeona Therapeutics (ABEO) and Applied Genetic Technologies (AGTC).

Company Calendar

Last Earnings
11/12/2021
Today
7/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ANGN
CIK
1601485
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.81 million
Net Margins
N/A
Pretax Margin
-4,456.97%
Return on Equity
-47.53%
Return on Assets
-40.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.00
Quick Ratio
20.00

Sales & Book Value

Annual Sales
$2.30 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.32 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
30,110,000
Free Float
24,182,000
Market Cap
$30.11 million
Optionable
Not Optionable
Beta
0.60
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ANGN) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners